HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$33.22
Day range
$33.08 - $33.52
Year range
$19.80 - $35.50
Market cap
1.88B USD
Avg Volume
658.83K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 8.19M | 46.00% |
Operating expense | 99.63M | 251.23% |
Net income | -81.55M | -0.66% |
Net profit margin | -995.84 | 31.06% |
Earnings per share | -1.45 | 1.36% |
EBITDA | -90.42M | -1.79% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | — | — |
Total assets | — | — |
Total liabilities | — | — |
Total equity | — | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | — | — |
Return on capital | -26.07% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -81.55M | -0.66% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
385